We've been producing a series of podcasts from our Lung Cancer Highlights from ASCO 2012 webinar, featuring Drs. Mark Socinski, from the University of Pittsburgh, and Joel Neal, from Stanford Cancer Center.  This program, and the series of podcasts produced from it, is part of our partnership of GRACE with the LUNGevity Foundation.

Here is the current list of the series of podcasts:

Dr. Socinski:

The PARAMOUNT trial of maintenance Alimta (pemetrexed)

Optimal chemo for marginal performance status patients with advanced NSCLC

TAILOR trial of Taxotere (docetaxel) vs. Tarceva (erlotinib) for EGFR mutation-negative advanced NSCLC

Update on critical small cell lung cancer trials from ASCO 2012

Dr. Neal:

Anti-PD1 Immunotherapy for Advanced NSCLC

Anti-MEK agent selumetinib for KRAS mutation-positive advanced NSCLC

LUX-Lung 3 trial of afatinib vs. chemo as first line therapy for advanced EGFR mutation-positive NSCLC

We've got just a few more to add from Dr. Neal, followed by a podcast that covers the question and answer session from this webinar.

What rank as your favorite highlights? Do you find this information to be encouraging, whether for immediate new possibilities or for longer term prospects for lung cancer?